In January 2025, a new vaccine for the European Medicine Agency's Medicine Products for Human Use (CHMP) recommended providing the Capvaxive marketing authority. This step is determined to expand the availability of Capvaxive in the EU and increase the options available to patients and health professionals who fight different diseases. This recommendation is an important milestone for the pharmaceutical industry, as it indicates the continuous growth of innovative agents and vaccines in the European market.
In April 2025, the European Commission provided approval for the MRNA-based vaccine, Abrysvo of physics, so that adults between 18 and 59 years of respiratory synchronous virus (RSV) in adults at increased risk of severe disease to prevent low-respiratory diseases. The approval came in March 2025 following a favorable recommendation from the European Medicine Agency expert panel. Abriswo's acceptance represents significant progress in the prevention of RSV, especially for high-risk individuals, and emphasizes the growing role of mRNA technology in addressing respiratory tract infections.
In May 2024, Modern MRNA vaccine, MRSWIA received approval from the American Food and Drug Administration (FDA) to prevent low respiratory disease due to RSV in 60 and over individuals. This marked the third RSV vaccine approved in the United States, which highlights the growing importance of dealing with RSVs, especially among old adults as a weak population. Modern success with Mrsvia is part of the widespread trend of taking advantage of MRNA technology for viral diseases, making the role of MRNA-based vaccines in public health stronger.
In October 2024, with a decline in sales of GSK's RSV vaccine, Arexvy, the company reported a 72% decline in sales during the third quarter. As a result, GSK revised its vaccine sales forecast for the year. Despite this shock, the company maintained a positive attitude and emphasized its strong vaccine pipeline and the ability to develop future products run by the upcoming product launch. The status of GSK reflects ups and downs in the vaccine market, where success may depend on factors such as market competition, public acceptance, and pricing strategies, but also emphasizes the ability to move forward in vaccine technology.
In December 2023, Biontech took an important step by inaugurating its first production facility in Africa, a bionet-based place in Kigali, Rwanda. The purpose of this new feature is to promote local vaccine production skills and improve access to vaccines throughout the continent, especially in undivided areas. This initiative is an important step in addressing global health inequalities to increase the availability of life vaccines in Africa, which can improve rapid reactions to the health infrastructure for future continents and continents.
Impact of Recent developments in Adult Vaccines Industry
The recommendation by the European Medicines Agency’s CHMP to grant marketing authorization for Capvaxive will significantly increase the availability of this vaccine in the European Union. For the adult vaccine market, this move represents an expansion of treatment options for various diseases, further diversifying the offerings available to healthcare providers. It also signals the ongoing growth of innovative vaccines, reinforcing the trend of continuous development within the industry. With more vaccines gaining approval, patients and healthcare professionals will have access to better and more diverse options, ultimately enhancing public health management across Europe. Additionally, the approval of new vaccines like Capvaxive can boost adult vaccine uptake by providing more tailored solutions for specific health needs, addressing concerns about vaccine efficacy, and encouraging greater confidence in vaccination programs. As more options become available, the accessibility and appeal of adult vaccines will increase, leading to higher vaccination rates and better protection against preventable diseases in the adult population. The approval of Pfizer's mRNA-based vaccine, Abrysvo, by the European Commission represents a major breakthrough in the prevention of respiratory syncytial virus (RSV) for adults at high risk. This development is particularly important as RSV affects adults with weakened immune systems, and this approval expands the market for vaccines targeting respiratory infections in the adult population. The growing role of mRNA technology in addressing respiratory diseases, such as RSV, highlights its potential for future vaccine development.
The approval of Moderna's Mresvia by the U.S. Food and Drug Administration (FDA) for preventing lower respiratory tract disease caused by RSV in adults aged 60 and older is another milestone in the adult vaccine market. This approval underscores the increasing recognition of the risks that RSV poses to elderly populations, a growing demographic. Mresvia is the third RSV vaccine approved in the U.S., reflecting the rising demand for treatments targeting respiratory infections in older adults. In line with Corporate Social Responsibility, Moderna’s commitment to improving public health extends beyond the approval of new vaccines. By ensuring that Mresvia is accessible to underserved populations, particularly those in low-income or rural areas, and implementing pricing models that account for economic disparities, Moderna can help ensure that older adults across various socioeconomic backgrounds have access to this life-saving vaccine. This focus on CSR not only drives vaccine uptake but also aligns with broader efforts to address health inequities, ultimately improving public health outcomes for the aging population.
The 72% decline in sales of GSK’s RSV vaccine, Arexvy, during the third quarter of 2024, highlights the challenges that pharmaceutical companies face in the competitive vaccine market. This sales slump and the subsequent revision of GSK’s vaccine sales forecast illustrate the unpredictable nature of the vaccine market, where factors such as competition, market acceptance, and pricing strategies play a crucial role. However, GSK's positive outlook, despite the setback, demonstrates the resilience of major vaccine manufacturers. To further enhance the corporate partnerships uptake, GSK can strengthen collaborations with healthcare providers, governments, and non-profit organizations to improve vaccine distribution and education, ensuring better access and increased demand. By working with these partners, GSK can address concerns regarding market acceptance, enhance public awareness of the vaccine's benefits, and refine pricing strategies to reach underserved populations. These partnerships will help GSK navigate the fluctuating market dynamics and ultimately increase the uptake of Arexvy and future vaccine offerings.
BioNTech’s inauguration of its first manufacturing facility in Africa in Kigali, Rwanda, represents a crucial step in addressing global health disparities. The facility aims to enhance local vaccine production capabilities and improve access to vaccines across the African continent. For the adult vaccine market, this development signals an important shift towards increasing the availability of vaccines in underserved regions. It also helps reduce the reliance on imported vaccines and builds a more resilient healthcare infrastructure in Africa.
According to Coherent Market Insights (CMI), the global Adult Vaccines Industry size is set to reach US$35.5 billion in 2032. Global Adult Vaccines Industry will likely increase at a CAGR of 8.6% during the forecast period.
Source:
News outlet: The Guardian, CNN, Reuters
